fda approval status cjc-1295 ipamorelin bpc-157 tb-500 aod-9604 October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee CJC-1295 No DAC (10mg) +
Description
The current FDA position on these peptides certainly puts a greater burden on consumers
Option b is incorrect as financial implications should not take precedence over the patient's wishes
Without compound-specific stability testing, the cleaner research assumption is to use the shorter window, reconstitute only what is needed, and label the vial immediately
Rare but Serious: Vision changes, severe pain in the pelvic area, or signs of blood clot formation like chest pain and difficulty breathing
